[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-vessel-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-vessel-disease":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100641709","biological-collection-of-the-rare-diseases-of-the-brain-and-eye-vessels-cohort---2-100641709",false,"NCT07650110","Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2","Collection Biologique de la Cohorte Des Maladies Rares Des Vaisseaux du Cerveau et de l'œil - 2","B-MRVC2","Inclusion Criteria:\n\nFor the group of patients with MVCR:\n\n* Patients aged between 18 and 80 years at the time of inclusion\n* Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL, or in another gene responsible for other forms of monogenic cSVD (such as the COL4A1, COL4A2 and HTRA1 genes) or a confirmed diagnosis of MOYA-MOYA (arteriography and\u002For genetic testing) or cavernoma, cerebral venous thrombosis or a cerebral vascular malformation, including cavernomas\n* Covered by social security or an equivalent scheme\n* Written consent.\n* Patient included in the MVCR cohort For control group\n* Subject aged between 18 and 80 at the time of inclusion.\n* Written consent.\n* Blood pressure \\\u003C 140\u002F90 mmHg without treatment or \\\u003C 130\u002F80 mmHg if treated and stable for ≥3 months\n* Covered by social security or a similar scheme\n* Strictly normal neurological examination (NIHSS=0; no focal deficit)\n* Normal cognitive examination: MMSE ≥ 26\n\nExclusion criteria :\n\nCommon exclusion criteria for patients and control subjects:\n\n* A person referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public Health Code, defined as:\n\n  * Pregnant women, women in labour or breastfeeding women\n  * Persons deprived of their liberty by judicial or administrative decision\n  * Persons hospitalised without consent and not subject to a legal protection measure, and persons admitted to a health or social care facility for purposes other than research\n  * Minors\n  * Adults subject to a legal protection measure (guardianship, curatorship or judicial protection), adults unable to give consent and not subject to a legal protection measure\n* Individuals subject to a withdrawal period for another research study\n* Patients participating in another interventional research study\n* Acute or chronic infectious disease\n\nSpecific exclusion criteria for control subjects\n\n* Any identified extra- or intracranial vascular pathology requiring specific management\n* Known cardiovascular disease (coronary artery disease, arterial disease, atrial fibrillation, heart failure)\n* Neurological history: stroke, TIA, intracranial haemorrhage, meningitis\u002Fencephalitis, head injury with loss of consciousness \\>30 mins,\n* Multiple sclerosis, neurodegenerative disease, active epilepsy,\n* Current or former smoking (more than 10 pack-years)\n* Diabetes\n* Antithrombotic or lipid-lowering treatment",true,"ALL","18 Years","80 Years",{"count":22,"type":23},600,"ESTIMATED","INTERVENTIONAL",[26],"NA","CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005. Since 2017, CERVCO has coordinated the MRVC cohort, a prospective cohort of patients with rare vascular diseases of the brain and retina, and established the associated B-MRVC biobank in 2020 to support translational research and biomarker discovery.\n\nDue to the rarity and heterogeneity of these disorders, centralized longitudinal collection of clinical data and biological samples is essential to improve understanding of disease mechanisms, identify biomarkers of progression and prognosis, and facilitate the development of new diagnostic and therapeutic approaches.\n\nThe present study aims to expand this longitudinal biobank, enable national and international collaborative research through controlled sample sharing, and establish reference control samples to support biomarker validation.",[29,30,31,32],"CADASIL","Cavernous Angioma","Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy","Small Vessel Disease",[34,35,36,37,30,38],"Brain Small Vessel Disease","Cadasil","Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy","Central Nervous System Vascular Malformations","Central Nervous System","NOT_YET_RECRUITING","2026-06-10",{"date":42,"type":43},"2026-06-16","ACTUAL",{"date":45,"type":23},"2026-06-30",{"date":47,"type":23},"2038-06-30",{"name":49,"class":50},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":77,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100462387","translational-immunodiagnostics-in-stroke-trims-100462387","NCT05300997","Translational Immunodiagnostics in Stroke (TrImS)","Translational Immunodiagnostics in Suspected Stroke (TrImS): A Two-centre, Pragmatic, Prospective, Observational Study","TrImS","Inclusion Criteria:\n\n* Patients eligible for enrolment include:\n\n  * Adults ≥18 years of age.\n  * Suspected acute stroke. Defined as either FAST-positive, or LAPSS-positive or ROSIER\\>0\n  * Within 24 hours of symptom onset.\n  * Informed consent.\n* Control subjects will be drawn from two groups:\n\n  * Non-neurologic patients who are matched with TIA and stroke cases (AIS, HS) for age, race, gender and smoking plus one or more of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidaemia.\n  * Relatives or accompanying friends.\n* Note that we will include and collect samples from the following cases if they present as suspected stroke and are recruited \\\u003C24 hours from symptom onset.\n\n  * Any central nervous system infection, i.e. meningitis or encephalitis in the past 30 days\n  * Any form of head trauma, stroke or intracranial haemorrhage in the past 30 days\n  * Known primary or metastatic cancer involving the brain\n  * Active cancer is defined as a diagnosis of cancer, within 6 months before enrollment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer.\n  * Autoimmune diseases: such as lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis\n  * Active infectious diseases (e.g. HIV\u002FAIDS, hepatitis C)\n  * Major surgery within three months prior to the index event\n\nExclusion Criteria:\n\n* Clear onset of acute symptoms \\>24 hours.","100 Years",{"count":61,"type":23},650,"1 Year","OBSERVATIONAL","In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim:\n\n1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis.\n2. to identify early brain- and pathology-specific, panorOmic biomarkers in saliva that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis.\n3. to derive biomarker platforms of models for early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis\n4. to validate these models in independent and external datasets",[66,67,68,69,70,32,71,72,73,74,75,76],"Acute Ischemic Stroke","Haemorrhagic Stroke","Transient Ischemic Attacks","Cardioembolic Stroke","Large-Artery Atherosclerosis (Embolus\u002FThrombosis)","Stroke of Other Determined Etiology","Stroke of Undetermined Etiology","Atrial Fibrillation","Stroke of Anterior Cerebral Artery","Stroke of Middle Cerebral Artery","Stroke of Basilar Artery",[78,79,80,81,82,83],"acute stroke","emergency medicine","diagnostics","molecular","genomics and transcriptomics","proteomics","RECRUITING","2026-05-07",{"date":87,"type":43},"2026-05-11",{"date":89,"type":43},"2022-05-01",{"date":91,"type":23},"2027-08-31",{"name":93,"class":50},"The University of Hong Kong",1]